Evidence map›Paper›PMID 25657017›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2015

Improved innate immune responses by Frondanol A5, a sea cucumber extract, prevent intestinal tumorigenesis.

Naveena B Janakiram, Altaf Mohammed, Taylor Bryant, Stan Lightfoot, Peter D Collin, Vernon E Steele, Chinthalapally V Rao

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05194007 (A Pilot Randomized, Double-blind, Placebo-controlled Trial to Investigate the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease), which is not on this map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
6.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05194007 phase2 / phase3completednot on this mapstarted 2022, after this paper: background citation

A Pilot Randomized, Double-blind, Placebo-controlled Trial to Investigate the Anti-inflammatory Effects of Frondanol in Adults With Inflammatory Bowel Disease

TypeinterventionalSponsorMohammed Bin Rashid University of Medicine and Health SciencesRan2022 to 2024Enrolled13ConditionsUlcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Crohn ColitisArmsFrondanol, Placebo
3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Northern Sea Cucumber (Marine drugs · 2020
    Review
  10. Article
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Naveena B JanakiramCenter for Cancer Prevention and Drug Development, Department of Medicine, Hem-Onc Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. cv-rao@ouhsc.edu naveena-janakiram@ouhsc.edu.
Altaf MohammedCenter for Cancer Prevention and Drug Development, Department of Medicine, Hem-Onc Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Taylor BryantCenter for Cancer Prevention and Drug Development, Department of Medicine, Hem-Onc Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Stan LightfootCenter for Cancer Prevention and Drug Development, Department of Medicine, Hem-Onc Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Peter D CollinCoastside Bio Resources, Deer Isle, Maine.
Vernon E SteeleDivision of Cancer Prevention, Chemopreventive Agent Development Research Group, National Cancer Institute, Bethesda, Maryland.
Chinthalapally V RaoCenter for Cancer Prevention and Drug Development, Department of Medicine, Hem-Onc Section, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma. cv-rao@ouhsc.edu naveena-janakiram@ouhsc.edu.
University of Oklahoma Health Sciences Center · USCoastside Bio Resources (United States) · USNational Cancer Institute · US

Funding

HMG-CoA Reductase and Polyamine Inhibitors for Prevention of Colorectal CancerR01CA094962 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAO, CHINTHALAPALLY V. · 2002 to 2014
$3.4M
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORSR01CA109247 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI RAO, CHINTHALAPALLY V. · 2004 to 2008
$1.5M
NCI NIH HHS N01 CN053300NCI NIH HHS N01-CN-53300NCI NIH HHS R01 CA094962NCI NIH HHS R01CA094962NCI NIH HHS R01 CA109247
6 · The paper itself

Abstract

Sea cucumbers are a source of antibacterial, anti-inflammatory, and anticancer compounds. We show that sea cucumber extract Frondanol A5 is capable of enhancing innate immune responses and inhibiting intestinal tumors in APC(Min/+) mice. APC(Min/+) mice were fed semi-purified diets containing 0, 250, or 500 ppm FrondanolA5 for 14 weeks before we assessed intestinal tumor inhibition. Dietary Frondanol A5 suppressed small intestinal polyp sizes and formation up to 30% (P < 0.02) in males and up to 50% (P < 0.01) in females. Importantly, 250 and 500 ppm Frondanol A5 diet suppressed colon tumor multiplicities by 65% (P < 0.007) and 75% (P < 0.0001), compared with untreated male APC(Min/+) mice. In female APC(Min/+) mice, both dose levels of Frondanol A5 suppressed colon tumor multiplicities up to 80% (P < 0.0001). Isolated peritoneal macrophages from treated mice showed increased phagocytosis efficiency (control 24% vs. treated 50%; P < 0.01) and an increase in GILT mRNA expression, indicating increased innate immune responses by these cells in treated animals. Similarly, we observed an increase in GILT expression in treated tumors, compared with untreated tumors. Furthermore, an increase in G-CSF cytokine, a decrease in inflammatory cytokines and marker 5-LOX, its regulator FLAP, proliferation (PCNA), and angiogenesis (VEGF) markers were observed in treatment groups. These data suggest that Frondanol A5 decreased inflammatory angiogenic molecules and increased GILT expression and macrophage phagocytosis. These decreases may have improved the innate immune systems of the treated mice, thus aiding in inhibition of intestinal tumor formation. These results suggest that Frondanol A5 exhibits significant chemopreventive potential against intestinal tumorigenesis.

Indexed as

AnimalsApoptosisBlotting, WesternCell ProliferationCells, CulturedCell Transformation, NeoplasticComplex MixturesCytokinesFemaleGenes, APCHumansImmunity, InnateImmunoenzyme TechniquesInflammation MediatorsIntestinal NeoplasmsMacrophages, PeritonealComplex MixturesCytokinesFrondanol-A5PIfi30 protein, mouseInflammation MediatorsOxidoreductasesOxidoreductases Acting on Sulfur Group DonorsRNA, Messenger

Identifiers

PMID25657017
PMCPMC4839268
OpenAlexW2164292821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.